@article{3d99b08f3b0f442da6fcdda6d166935d,
title = "Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial",
abstract = "Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant of treatment response. Dose-dense (DD) temozolomide results in prolonged depletion of MGMT in blood mononuclear cells and possibly in tumor. This trial tested whether DD temozolomide improves overall survival (OS) or progression-free survival (PFS) in patients with newly diagnosed GBM.",
author = "Gilbert, {Mark R} and Meihua Wang and Aldape, {Kenneth D} and Roger Stupp and Hegi, {Monika E} and Jaeckle, {Kurt A} and Armstrong, {Terri S} and Wefel, {Jeffrey S} and Minhee Won and Blumenthal, {Deborah T} and Anita Mahajan and Schultz, {Christopher J} and Sara Erridge and Brigitta Baumert and Hopkins, {Kristen I} and Tzahala Tzuk-Shina and Brown, {Paul D} and Arnab Chakravarti and Curran, {Walter J} and Mehta, {Minesh P}",
year = "2013",
month = oct,
day = "7",
doi = "10.1200/JCO.2013.49.6968",
language = "English",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
}